Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Fineline Cube Jan 19, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Medical Device

United Imaging Installs AI-Powered uMR OMEGA at XRANM’s Breast Health Center

Fineline Cube Nov 22, 2024

Shanghai-based United Imaging Healthcare Co., Ltd. has announced the installation of an ultra-wide-bore AI-empowered uMR...

Company Drug

Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA

Fineline Cube Nov 21, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced the submission of a New Drug Application...

Company Deals

Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China

Fineline Cube Nov 21, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between...

Company Drug

Innovent Biologics’ IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment

Fineline Cube Nov 21, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Innovent Biologics, Inc. (HKG:...

Company Drug

CDE Includes Double-Crane’s Hydroxocobalamine and Sanofi Genzyme’s Fitusiran in Rare Disease Care Plan

Fineline Cube Nov 21, 2024

China’s Center for Drug Evaluation (CDE) has announced the inclusion of China Resources Double-Crane Pharmaceutical...

Company Drug

Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency

Fineline Cube Nov 21, 2024

Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco,...

Company Deals

BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China

Fineline Cube Nov 21, 2024

German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...

Company Medical Device

Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection

Fineline Cube Nov 21, 2024

US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...

Company Deals

CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa

Fineline Cube Nov 21, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...

Company Drug

NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases

Fineline Cube Nov 21, 2024

The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...

Company Drug

Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B

Fineline Cube Nov 21, 2024

US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Fineline Cube Nov 21, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...

Company Deals

Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion

Fineline Cube Nov 21, 2024

China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...

Company Drug

US FDA Grants ODD to Ractigen’s siRNA Therapy RAG-21 for ALS Treatment

Fineline Cube Nov 21, 2024

China-based small activating RNA (saRNA) drug developer, Ractigen Therapeutics, has announced that it has received...

Company Drug

UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa

Fineline Cube Nov 21, 2024

Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...

Company Deals

Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies

Fineline Cube Nov 21, 2024

US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...

Legal / IP

BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa

Fineline Cube Nov 21, 2024

China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...

Company Deals

Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102

Fineline Cube Nov 20, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...

Company Drug

GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus

Fineline Cube Nov 20, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...

Company Drug

Astellas Pharma’s Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter

Fineline Cube Nov 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4568) has announced that its supplemental New Drug Application (sNDA)...

Posts pagination

1 … 207 208 209 … 611

Recent updates

  • Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise
  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.